纳米递送系统在乳腺癌治疗中的研究进展

李国庆; 焦萍; 王瑞芳; 张杜娟

doi:10.6039/j.issn.1001-0408.2023.01.24

您当前的位置：

首页 >

文章列表页 >

纳米递送系统在乳腺癌治疗中的研究进展

综述 | 更新时间：2023-02-22

- 纳米递送系统在乳腺癌治疗中的研究进展
- Research progress of nano delivery system in breast cancer treatment
- 中国药房 2023年34卷第1期页码：122-128
- 作者机构：
  
  济南市妇幼保健院药剂科，济南　250002
- 作者简介：
  
  主管药师，硕士。研究方向：药物制剂。电话：0531-89029776。E-mail：liguoqing-1001@163.com
  主管药师，硕士。研究方向：药物制剂。电话：0531-89029776。E-mail：447800440@qq.com
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2023.01.24
  中图分类号： R944
- 纸质出版日期：2023-01-15，
  
  收稿日期：2022-08-02，
  
  修回日期：2022-11-29，
扫描看全文
李国庆,焦萍,王瑞芳等.纳米递送系统在乳腺癌治疗中的研究进展[J].中国药房,2023,34(01):122-128.

LI Guoqing,JIAO Ping,WANG Ruifang,et al.Research progress of nano delivery system in breast cancer treatment[J].ZHONGGUO YAOFANG,2023,34(01):122-128.
李国庆,焦萍,王瑞芳等.纳米递送系统在乳腺癌治疗中的研究进展[J].中国药房,2023,34(01):122-128. DOI： 10.6039/j.issn.1001-0408.2023.01.24.

LI Guoqing,JIAO Ping,WANG Ruifang,et al.Research progress of nano delivery system in breast cancer treatment[J].ZHONGGUO YAOFANG,2023,34(01):122-128. DOI： 10.6039/j.issn.1001-0408.2023.01.24.

摘要

乳腺癌是当下严重威胁女性健康的一种恶性肿瘤，手术治疗虽然最直接有效，但是受诸多因素限制，需辅助以其他的治疗方式。这些辅助治疗方式除常规放疗外，还有化疗、基因治疗、光疗等，但是化疗、基因治疗、光疗等使用的治疗剂往往存在水溶性、稳定性、靶向性差等缺点。随着纳米技术的出现，越来越多的学者构建并研究了治疗乳腺癌的纳米递送系统，如基于肿瘤微环境设计的响应系统、温敏响应性系统、基于肿瘤细胞膜表面特有蛋白的纳米递送系统等。笔者对此进行总结发现，这些纳米递送系统不仅提高了治疗剂的水溶性、稳定性，还能采用靶向手段等方式将其精准地递送到乳腺肿瘤部位，在提高疗效的同时降低毒副作用，可为乳腺癌的治疗药物开发和临床应用提供参考。

Abstract

Breast cancer is a malignant tumor that seriously threatens women’s health at present. Although surgical treatment is the most direct and effective， it is limited by many factors and needs to be assisted by other treatments. In addition to conventional radiotherapy， these adjuvant therapies also include chemotherapy， gene therapy， phototherapy and so on. However， the therapeutic agents used in these treatment methods have some limitations， such as poor water-solubility， instability and targeting. With the development of nano-technology， more and more researchers construct and study nano delivery system for breast tumor treatment， such as response system designed based on tumor microenvironment， temperature sensitive response system， nano delivery system based on specific proteins of tumor cell membrane， etc. The author summarizes the nano delivery system， and finds that these nano delivery systems can not only improve the water-solubility and stability of the therapeutic agents， but also accurately deliver them to the breast tumor site by targeted means， improve the efficacy and reduce toxic side effects， which provides new ideas for the treatment of breast cancer in the future.

关键词

纳米递送体系乳腺癌化疗基因治疗光疗

Keywords

breast cancerchemotherapygene therapyphototherapy

references

ZHONG D，ZHANG D，XIE T，et al. Biodegradable microalgae-based carriers for targeted delivery and imaging-guided therapy toward lung metastasis of breast cancer[J]. Small，2020，16（20）：e2000819.

WANG Z，ZHAO Y，YANG Z，et al. Construction of intelligent responsive drug delivery system and multi-mode imaging based on gold nanodots[J]. Macromol Rapid Commun，2022，43（10）：e2200034.

GUO Z，SUI J，MA M，et al. pH-responsive charge switcha- ble PEGylated ε-poly-l-lysine polymeric nanoparticles-assisted combination therapy for improving breast cancer treatment[J]. J Control Release，2020，326：350-364.

SINGH S，GHOSH C，ROY P，et al. Biosynthesis of folic acid appended PHBV modified copper oxide nanorods for pH sensitive drug release in targeted breast cancer therapy[J]. Int J Pharm，2022，622：121831.

MA W，SUN J，XU J，et al. Sensitizing triple negative breast cancer to tamoxifen chemotherapy via a redox-responsive vorinostat-containing polymeric prodrug nanocarrier[J]. Theranostics，2020，10（6）：2463-2478.

DONG C，ZHOU Q，XIANG J，et al. Self-assembly of oxidation-responsive polyethylene glycol-paclitaxel prodrug for cancer chemotherapy[J]. J Control Release，2020，321：529-539.

TANG M X，YANG M J，HE K Y，et al. Glycyrrhetinic acid remodels the tumor microenvironment and synergizes with doxorubicin for breast cancer treatment in a murine model[J]. Nanotechnology，2021，32（18）：185702.

GUO Y，LIU S，LUO F，et al. A nanosized codelivery system based on intracellular stimuli-triggered dual-drug release for multilevel chemotherapy amplification in drug-resistant breast cancer[J]. Pharmaceutics，2022，14（2）：422.

ZHANG H，TANG W L，KHEIROLOMOOM A，et al. Development of thermosensitive resiquimod-loaded liposomes for enhanced cancer immunotherapy[J]. J Control Release，2021，330：1080-1094.

LI R，LIN Z，ZHANG Q，et al. Injectable and in situ-formable thiolated chitosan-coated liposomal hydrogels as curcumin carriers for prevention of in vivo breast cancer recurrence[J]. ACS Appl Mater Interfaces，2020，12（15）：17936-17948.

TANG Z，LUO C，JUN Y，et al. Nanovector assembled from natural egg yolk lipids for tumor-targeted delivery of therapeutics[J]. ACS Appl Mater Interfaces，2020，12（7）：7984-7994.

LANDGRAF M，LAHR C A，KAUR I，et al. Targeted camptothecin delivery via silicon nanoparticles reduces breast cancer metastasis[J]. Biomaterials，2020，240：119791.

YADAV A S，RADHARANI N N V，GORAIN M，et al. RGD functionalized chitosan nanoparticle mediated targeted delivery of raloxifene selectively suppresses angiogenesis and tumor growth in breast cancer[J]. Nanoscale，2020，12（19）：10664-10684.

BHATTACHARYA S，GHOSH A，MAITI S，et al. Delivery of thymoquinone through hyaluronic acid-decorated mixed pluronic® nanoparticles to attenuate angiogenesis and metastasis of triple-negative breast cancer[J]. J Control Release，2020，322：357-374.

YIN S，GAO Y，ZHANG Y，et al. Reduction/oxidation-responsive hierarchical nanoparticles with self-driven degradability for enhanced tumor penetration and precise chemotherapy[J]. ACS Appl Mater Interfaces，2020，12（16）：18273-18291.

SHI J，REN Y，MA J，et al. Novel CD44-targeting and pH/redox-dual-stimuli-responsive core-shell nanoparticles loading triptolide combats breast cancer growth and lung metastasis[J]. J Nanobiotechnology，2021，19（1）：188.

KIM B，SHIN J，WU J，et al. Engineering peptide-targeted liposomal nanoparticles optimized for improved selecti- vity for HER2-positive breast cancer cells to achieve enhanced in vivo efficacy[J]. J Control Release，2020，322：530-541.

QIU Y，RENK，ZHAOW，et al. A “dual-guide” bioinspired drug delivery strategy of a macrophage-based carrier against postoperative triple-negative breast cancer recurrence[J]. J Control Release，2021，329：191-204.

GONG C，YU X，YOU B，et al. Macrophage-cancer hybrid membrane-coated nanoparticles for targeting lung metastasis in breast cancer therapy[J]. J Nanobiotechnology，2020，18（1）：92.

DU W，CHEN C，SUN P，et al. Eliciting an immune hot tumor niche with biomimetic drug-based multi-functional nanohybrids augments immune checkpoint blockade-based breast cancer therapy[J]. Nanoscale，2020，12（5）：3317-3329.

MEI D，GONG L，ZOU Y，et al. Platelet membrane-cloaked paclitaxel-nanocrystals augment postoperative chemotherapeutical efficacy[J]. J Control Release，2020，324：341-353.

LI J Q，ZHAO R X，YANG F M，et al. An erythrocyte membrane-camouflaged biomimetic nanoplatform for enhanced chemo-photothermal therapy of breast cancer[J]. J Mater Chem B，2022，10（12）：2047-2056.

LI S，WU Y，DING F，et al. Engineering macrophage-derived exosomes for targeted chemotherapy of triple-negative breast cancer[J]. Nanoscale，2020，12（19）：10854-10862.

HU M，ZHANG J，KONG L，et al. Immunogenic hybrid nanovesicles of liposomes and tumor-derived nanovesicles for cancer immunochemotherapy[J]. ACS Nano，2021，15（2）：3123-3138.

ZHAO Z，LI Y，SHUKLA R，et al. Development of a biocompatible copolymer nano complex to deliver VEGF siRNA for triple negative breast cancer[J]. Theranostics，2019，9（15）：4508-4524.

JUNEJA R，VADAREVU H，HALMAN J，et al. Combination of nucleic acid and mesoporous silica nanoparticles：optimization and therapeutic performance in vitro[J]. ACS Appl Mater Interfaces，2020，12（35）：38873-38886.

ZHANG Y，TENG Z，NI Q，et al. Orderly curled silica nanosheets with a small size and macromolecular loading pores：synthesis and delivery of macromolecules to eradicate drug-resistant cancer[J]. ACS Appl Mater Interfaces，2020，12（52）：57810-57820.

JIN M，HOU Y，QUAN X，et al. Smart polymeric nanoparticles with pH-responsive and PEG-detachable properties （Ⅱ）：co-delivery of paclitaxel and VEGF siRNA for synergistic breast cancer therapy in mice[J]. Int J Nanomedicine，2021，16：5479-5494.

LIU H，LIU C，YE L，et al. Nanoassemblies with effective serum tolerance capability achieving robust gene silencing efficacy for breast cancer gene therapy[J]. Adv Mater，2021，33（7）：e2003523.

LI Y，DING J，XU X，et al. Dual hypoxia-targeting RNAi nanomedicine for precision cancer therapy[J]. Nano Lett，2020，20（7）：4857-4863.

XU J，LIU Y，LI Y，et al. Precise targeting of POLR2A as a therapeutic strategy for human triple negative breast cancer[J]. Nat Nanotechnol，2019，14（4）：388-397.

LIU S，ZHANG Y，ZHAO X，et al. Tumor-specific silen- cing of tissue factor suppresses metastasis and prevents cancer-associated hypercoagulability[J]. Nano Lett，2019，19（7）：4721-4730.

LI G，GAO Y，GONG C，et al. Dual-blockade immune checkpoint for breast cancer treatment based on a tumor-penetrating peptide assembling nanoparticle[J]. ACS Appl Mater Interfaces，2019，11（43）：39513-39524.

ZHANG L，MU C，ZHANG T，et al. Development of targeted therapy therapeutics to sensitize triple-negative breast cancer chemosensitivity utilizing bacteriophage phi29 derived packaging RNA[J]. J Nanobiotechnology，2021，19（1）：13.

ZHANG L，MU C，ZHANG T，et al. Systemic delivery of aptamer-conjugated XBP1 siRNA nanoparticles for efficient suppression of HER2+ breast cancer[J]. ACS Appl Mater Interfaces，2020，12（29）：32360-32371.

ZHAO L，GU C，GAN Y，et al. Exosome-mediated siRNA delivery to suppress postoperative breast cancer metastasis[J]. J Control Release，2020，318：1-15.

HA M，NAM S H，SIM K，et al. Highly efficient photothermal therapy with cell-penetrating peptide-modified bumpy Au triangular nanoprisms using low laser power and low probe dose[J]. Nano Lett，2021，21（1）：731-739.

TAHERI-LEDARI R，ZHANG W，RADMANESH M，et al. Multi-stimuli nanocomposite therapeutic：docetaxel targeted delivery and synergies in treatment of human breast cancer tumor[J]. Small，2020，16（41）：e2002733.

LI L，FU J，WANG X Y，et al. Biomimetic “nanoplatelets” as a targeted drug delivery platform for breast cancer theranostics[J]. ACS Appl Mater Interfaces，2021，13（3）：3605-3621.

ZHOU M，XING Y，LI X，et al. Cancer cell membrane camouflaged semi-Yolk@Spiky-shell nanomotor for enhanced cell adhesion and synergistic therapy[J]. Small，2020，16（39）：e2003834.

CHEN Y，ZHANG X H，CHENG D B，et al. Near-infrared laser-triggered in situ dimorphic transformation of BF2-azadipyrromethene nanoaggregates for enhanced solid tumor penetration[J]. ACS Nano，2020，14（3）：3640-3650.

ZHANG Y，WANG Q，MA T，et al. Tumor targeted combination therapy mediated by functional macrophages under fluorescence imaging guidance[J]. J Control Release，2020，328：127-140.

QIAO J，TIAN F，DENG Y，et al. Bio-orthogonal click-targeting nanocomposites for chemo-photothermal synergistic therapy in breast cancer[J]. Theranostics，2020，10（12）：5305-5321.

LIU R，AN Y，JIA W，et al. Macrophage-mimic shape changeable nanomedicine retained in tumor for multimodal therapy of breast cancer[J]. J Control Release，2020，321：589-601.

LIU P，PENG Y，ZHOU Y，et al. Rapamycin as a “one-stone-three-birds” agent for cooperatively enhanced phototherapies against metastatic breast cancer[J]. ACS Appl Mater Interfaces，2021，13（22）：25674-25684.

ZHU Y X，JIA H R，DUAN Q Y，et al. Photosensitizer-doped and plasma membrane-responsive liposomes for nuclear drug delivery and multidrug resistance reversal[J]. ACS Appl Mater Interfaces，2020，12（33）：36882-36894.

HU S，DONG C，WANG J，et al. Assemblies of indocyanine green and chemotherapeutic drug to cure established tumors by synergistic chemo-photo therapy[J]. J Control Release，2020，324：250-259.

YI H，LU W，LIU F，et al. ROS-responsive liposomes with NIR light-triggered doxorubicin release for combinatorial therapy of breast cancer[J]. J Nanobiotechnology，2021，19（1）：134.

WANG X，LIU Y，HU Y，et al. Hybrid micelles loaded with chemotherapeutic drug-photothermal agent realizing chemo-photothermal synergistic cancer therapy[J]. Eur J Pharm Sci，2022，175：106231.

TANG L，WANG Z，MU Q，et al. Targeting neutrophils for enhanced cancer theranostics[J]. Adv Mater，2020，32（33）：e2002739.

LI X，JEON Y H，KWON N，et al. In vivo-assembled phthalocyanine/albumin supramolecular complexes combined with a hypoxia-activated prodrug for enhanced photodynamic immunotherapy of cancer[J]. Biomaterials，2021，266：120430.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

JAK抑制剂治疗白癜风的研究进展